avatar for Thomas Kosten, MD

Thomas Kosten, MD

JH Waggoner Chair and Professor of Psychiatry, Neuroscience, Pharmacology, and Immunology, Baylor College of Medicine, Houston, Texas

Thomas R. Kosten, MD, is the JH Waggoner Chair and Professor of Psychiatry, Pharmacology and Neuroscience, vice-Chair for Psychiatry and Co-director of the Dan L. Duncan Institute for Clinical and Translational Research at Baylor College of Medicine. His other key appointments are Distinguished Professor of Psychiatry at Peking University Medical School and Professor of Epidemiology and of Behavioral Health at MD Anderson Cancer Prevention Center. He is a former Professor at Yale University School of Medicine, the founding Vice Chair for Addiction Psychiatry of the American Board of Psychiatry and Neurology, and Past President of both the American Academy of Addiction Psychiatry and the College on Problems of Drug Dependence. He is a Distinguished Life Fellow in the American Psychiatric Association and a Fellow of the American College of Neuropsychopharmacology. He has served as a Congressional Fellow in the U.S. House of Representatives and has been a long-standing member of various substance abuse commissions for the National Academy of Sciences as well as various advisory boards for the Food and Drug Administration and the Department of Defense, primarily related to veteran health and drug safety and risk management. Since 2001, based on an annual ranking by U.S. News & World Report, Dr. Kosten has retained the distinction of “Top Doc” in the field of Psychiatry; rated in the top 10%, as well as in the field of Addictions Medicine, rated in the top 1%, of U.S. physicians nationwide. He is the current Editor for the American Journal on Addictions, past Editor for the American Journal of Drug and Alcohol Abuse, and serves on the board of several notable journals in substance abuse. He has published over 600 papers, books, and reviews describing his medication contributions including vaccines for cocaine, opiates and methamphetamine, and disulfiram as a pharmacogenetic treatment for cocaine dependence.